FDA Approves Juvmo, a New Once-Daily Pill for Parkinson's Disease

The U.S. Food and Drug Administration (FDA) has approved Juvmo (tavapadon), a new once-daily pill for adults with Parkinson's disease. This medication offers a new treatment option by selectively activating D1 and D5 dopamine receptors. Clinical trials demonstrated improvements in movement-related scores for patients with early Parkinson's and an average increase of 1.1 hours of daily 'on' time when used alongside levodopa. The FDA's approval was granted on September 25, 2026, with manufacturer AbbVie announcing plans for its availability in October.